Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 943

The DOI matches its Crossref record; 198 of the 198 references it cites were found in a registry or an index.

Androgen receptor: structure, role in prostate cancer and drug discovery

Open access
Tan, MH Eileen, Li, Jun, Xu, H Eric, Melcher, Karsten, Yong, Eu-leong·2015·Acta Pharmacologica Sinica

Abstract

Androgens and androgen receptors (AR) play a pivotal role in expression of the male phenotype. Several diseases, such as androgen insensitivity syndrome (AIS) and prostate cancer, are associated with alterations in AR functions. Indeed, androgen blockade by drugs that prevent the production of androgens and/or block the action of the AR inhibits prostate cancer growth. However, resistance to these drugs often occurs after 2-3 years as the patients develop castration-resistant prostate cancer (CRPC). In CRPC, a functional AR remains a key regulator. Early studies focused on the functional domains of the AR and its crucial role in the pathology. The elucidation of the structures of the AR DNA binding domain (DBD) and ligand binding domain (LBD) provides a new framework for understanding the functions of this receptor and leads to the development of rational drug design for the treatment of prostate cancer. An overview of androgen receptor structure and activity, its actions in prostate cancer, and how structural information and high-throughput screening have been or can be used for drug discovery are provided herein.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/aps.2014.18

Cites

198 of 198 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 198 references

Research works printed but not linked: 9

  1. Marte B . Passage through the nuclear pore. Nat Cell Biol 2001; 3: E135. · doi:10.1038/35078596
  2. Goulioumis AK, Varakis J, Goumas P, Papadaki H . Androgen receptor in laryngeal carcinoma: could there be an androgen-refractory tumor? ISRN Oncol 2011; 2011: 180518.
  3. Garolla A, Ferlin A, Vinanzi C, Roverato A, Sotti G, Artibani W, et al. Molecular analysis of the androgen receptor gene in testicular cancer. Endocr Relat Cancer 2005; 12: 645–55. · doi:10.1677/erc.1.00954
  4. Silva Neto B, Koff WJ, Biolchi V, Brenner C, Biolo KD, Spritzer PM, et al. Polymorphic CAG and GGC repeat lengths in the androgen receptor gene and prostate cancer risk: analysis of a Brazilian population. Cancer Invest 2008; 26: 74–80. · doi:10.1080/07357900701638251
  5. Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, et al. Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial. J Urol 2010; 184: 2297–302. · doi:10.1016/j.juro.2010.08.005
  6. Zeliadt SB, Buist DS, Reid RJ, Grossman DC, Ma J, Etzioni R . Biopsy follow-up of prostate-specific antigen tests. Am J Prev Med 2012; 42: 37–43. · doi:10.1016/j.amepre.2011.08.024
  7. Marx J . Medicine. Fused genes may help explain the origins of prostate cancer. Science 2005; 310: 603. · doi:10.1126/science.310.5748.603a
  8. Van Poppel H, Klotz L . Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol 2012; 19: 594–601. · doi:10.1111/j.1442-2042.2012.02997.x
  9. Berruti A, Generali D, Tampellini M . Enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 2448. · DOI

Cited by

Metadata

Authors
Tan, M. E., Li, J., Xu, H. E., Melcher, K., & Yong, E.-L.
Venue
Acta Pharmacologica Sinica
Published
2014-06-09
Volume
36
Issue
1
Pages
3-23
ISSN
  • 0253-9756 (ISSN-L)
  • 1671-4083
  • 1745-7254
OpenAlex
W1968786809
Cited by
943
References
198
FWCI
25.69
Type
journal article
Language
en
Open access
hybrid
Licence
creativecommons.org/licenses/by-nc-nd/3.0 (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.